Compounds acting on pathogenic pathways of pulmonary arterial hypertension. Compounds acting on pathogenic pathways of pulmonary arterial hypertension.

Slides:

Advertisements

Similar presentations

BDNF: brain-derived neurotrophic factor CRP: C-reactive protein

Advertisements

Volume 75, Issue 1, Pages (January 2010)

Copyright © 2003 American Medical Association. All rights reserved.

Growth factors Polypeptides in nature

Volume 125, Issue 1, Pages (July 2003)

Endothelium-derived mediators: the vasodilators prostacyclin (PGI2) and nitric oxide (NO) and the vasoconstrictor endothelin (ET-1). Endothelium-derived.

Figure 3 Extracellular stimuli to HSC activation

Volume 151, Issue 2, Pages (February 2017)

Chlamydophila pneumoniae

How do cells talk to each other

Frederic Rahbari-Oskoui, MD, MS American Journal of Kidney Diseases

Surgical removal of endometriotic lesions alters local and systemic proinflammatory cytokines in endometriosis patients Stephany P. Monsanto, M.Sc.,

S. S. Pullamsetti, R. Savai, W. Janssen, B. K. Dahal, W. Seeger, F

The key pathways and classes of drugs that have been approved for the treatment of pulmonary arterial hypertension. The key pathways and classes of drugs.

Kristopher G. Maier, PhD, Xuan Han, Benjamin Sadowitz, MD, Karen L

Physiological changes in pulmonary arterial hypertension (PAH) patients which occur in response to pregnancy. Physiological changes in pulmonary arterial.

Vascular endothelial dysfunction in cirrhosis

Daniel A. Langer, Vijay H. Shah Journal of Hepatology

The pro-inflammatory and chemotactic cytokine microenvironment of the abdominal aortic aneurysm wall: A protein array study Rachel K. Middleton, BSc,

Volume 151, Issue 2, Pages (February 2017)

Craig H Selzman, MD, Stephanie A Miller, MD, Alden H Harken, MD

Divya Gupta et al. JCHF 2013;1:

Familial history of hereditary haemorrhagic telangiectasis (HHT) of the 29-yr-old patient (•) with HHT and severe pulmonary arterial hypertension (PAH).

Hypoxia-inducible factor pathway and diseases of the vascular wall

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 1 Cytokine titers determined by the multiplex bead assay Plotted are cytokine titers (pg/mL) in CSF of patients with other noninflammatory neurologic.

Plexiform lesion from a patient with severe pulmonary hypertension demonstrating the exuberant proliferation of cells that comprise the lumen of the small.

Schematic diagram showing as yet unexplored pathophysiological mechanisms in pulmonary arterial hypertension (PAH). Schematic diagram showing as yet unexplored.

Thrombosis and Inflammatory Bowel Disease

Key pathways involved in the pathogenesis of pulmonary arterial hypertension: a) endothelin (ET) pathway; b) nitric oxide pathway; and c) prostacyclin.

The key pathological mechanisms underlying vascular changes in pulmonary hypertension (PH). The key pathological mechanisms underlying vascular changes.

Timeline of approval of therapies for pulmonary arterial hypertension.

An algorithm for the early diagnosis of pulmonary arterial hypertension in systemic sclerosis. An algorithm for the early diagnosis of pulmonary arterial.

Thomas Quaschning, Jan Galle, Christoph Wanner

Margus Annuk, Mihkel Zilmer, Bengt Fellström

Stefan Frank, Heiko Kämpfer, Christian Wetzler, Josef Pfeilschifter

Volume 70, Issue 10, Pages (November 2006)

Volume 125, Issue 1, Pages (July 2003)

Volume 86, Issue 2, Pages (August 2014)

Pathogenesis of idiopathic pulmonary fibrosis (IPF).

Pathophysiology of right ventricular (RV) failure.

Schematic diagram of endothelin (ET)-1 release in the human cardiovascular system. Schematic diagram of endothelin (ET)-1 release in the human cardiovascular.

Craig S. Stump, MD, PhD, Marc T. Hamilton, PhD, James R. Sowers, MD

Schematic illustration of the concepts in the pathogenesis of rheumatoid arthritis associated-interstitial lung disease (RA-ILD). Schematic illustration.

Why is proteinuria an ominous biomarker of progressive kidney disease?

Proteinase activated receptor-1 expression in a) weak immunostaining in normal lung tissue, b) intense immunostaining in idiopathic pulmonary fibrosis,

Proposed mechanisms for fibrointimal proliferation in pulmonary tumour thrombotic microangiopathy (PTTM). Proposed mechanisms for fibrointimal proliferation.

Survival in patients with pulmonary arterial hypertension based on aetiology. •: congenital heart disease; ▪: collagen vascular disease; ▵: HIV-related;

Renin–angiotensin system blockade and diabetes: moving the adipose organ from the periphery to the center Oliver Lenz, Alessia Fornoni Kidney International

Mechanisms of virus-induced airway inflammation in chronic obstructive pulmonary disease (COPD). Mechanisms of virus-induced airway inflammation in chronic.

Established and putative mediators and pathways involved in the pathogenesis of pulmonary arterial hypertension. Established and putative mediators and.

The effects of prostanoids on vasculature and blood cells; a variety of vascular cells, platelets and leukocytes have been identified as targets for the.

Alterations in expression of endometrial endothelial nitric oxide synthase and αvβ3 integrin in women with endometriosis Omid Khorram, M.D., Ph.D., Bruce.

Directed differentiation of hPSCs.

Inhibition of VEGF-R2-mediated signalling cascade by endogenous antagonists. Inhibition of VEGF-R2-mediated signalling cascade by endogenous antagonists.

Mechanism of action for pulmonary arterial hypertension medications.

Treatment algorithm. Treatment algorithm. IPAH: idiopathic pulmonary arterial hypertension; APAH: associated pulmonary arterial hypertension; WHO-FC: World.

Vallerie V. McLaughlin et al. JACC 2015;65:

Pulmonary arterial hypertension specific medication use at enrolment among previously diagnosed patients. 184 (7%) of patients were not on a prostaglandin,

Molecular pathways underlying angiogenesis.

Cardiac index (CI) changes from baseline following single oral doses of riociguat (○) 1 mg and 2.5 mg compared with inhaled nitric oxide (•) in patients.

Can we cure HIV-1-associated nephropathy in transgenic mice?

Nat. Rev. Endocrinol. doi: /nrendo

Proteinuria and hypertension with tyrosine kinase inhibitors

Diagnostic algorithm for chronic thromboembolic pulmonary hypertension

Cellular players and molecules in idiopathic pulmonary fibrosis (IPF) and systemic sclerosis-associated interstitial lung disease. Cellular players and.

Pathogenic concepts of pulmonary arterial hypertension (PAH).

Cardiac index (CI) changes from baseline following single oral doses of riociguat (Rio) compared with inhaled nitric oxide (NO) in patients with chronic.

Effect of placebo (n=88) and bosentan (n=80) on the co-primary end-point pulmonary vascular resistance (PVR) in the EARLY (Endothelial Antagonist Trial.

Overview of the dysfunctional metabolic pathways in pulmonary vascular cell types implicated in the development of pulmonary hypertension. Overview of.

Presentation transcript:

Compounds acting on pathogenic pathways of pulmonary arterial hypertension. Compounds acting on pathogenic pathways of pulmonary arterial hypertension. BMPR2: bone morphogenetic peptide receptor 2; VIP: vasoactive intestinal peptide; NO: nitric oxide; RANTES: regulated on activation, normal T-cell expressed and secreted; MCP: monocyte chemoattractant protein; IL: interleukin; PDGF: platelet-derived growth factor; EGF: epidermal growth factor; FGF: fibroblast growth factor; VEGF: vascular epidermal growth factor; PDK: pyruvate dehydrogenase kinase; PDH: pyruvate dehydrogenase; eNOS: endothelial nitric oxide synthase; BH4: tetrahydrobiopterin; ACE: angiotensin-converting enzyme; CCB: calcium channel blocker; HDAC: histone deacetylase; NFATc: nuclear factor of activated T-cells, cytoplasmic; PLC: phospholipase C; BMP: bone morphogenetic peptide; PPAR: peroxisome proliferator-activated receptor; NO2-FA: nitrated fatty acid; IP: prostaglandin receptor; ERA: endothelin receptor antagonist; PDE5-i: phosphodiesterase type-5 inhibitor. Nazzareno Galiè, and Ardeschir-Hossein Ghofrani Eur Respir Rev 2013;22:503-514 ©2013 by European Respiratory Society